Premium
Outcomes of a methicillin‐resistant Staphylococcus aureus (MRSA) eradication protocol in pediatric cystic fibrosis (CF) patients
Author(s) -
Belarski Emily,
Pettit Rebecca
Publication year - 2020
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.24628
Subject(s) - medicine , cystic fibrosis , methicillin resistant staphylococcus aureus , staphylococcus aureus , retrospective cohort study , surgery , biology , bacteria , genetics
Objective Methicillin‐resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis (CF) patients have greatly increased in prevalence in the past two decades and may lead to a more rapid rate of lung function decline. The objective of this study was to determine the impact of a MRSA eradication protocol on long‐term culture results and clinical outcomes of pediatric CF patients in a real‐world setting. Methods This was a single‐center, retrospective study of children age 30 days to 17 years. Eradication followed the STAR‐too study protocol. The primary outcome was the percent of patients with MRSA‐negative cultures at 12 months. Secondary outcomes were the percent of patients with negative cultures at 3, 6, and greater than 12 months and changes in clinical outcomes compared to individual baseline. Results Of the 55 patients who met inclusion criteria, 10 received protocol eradication. Baseline characteristics were similar between eradication and control groups except more eradication patients were on ivacaftor (30% vs 4%; P = .037). Two eradication patients did not receive rifampin due to ivacaftor use. Eradication did not significantly increase the percent of MRSA‐negative cultures at 3 months ( P = .122), 6 months ( P = .058), or 12 months ( P = .108); however, did increase culture negativity at greater than 12 months ( P = .008). Eradication resulted in no significant differences in clinical outcomes compared to control. Conclusions An extensive eradication protocol may lead to an increased clearance rate of long‐term CF respiratory cultures but does not appear to affect clinical outcomes. Eradication may be reasonable to attempt; however, more data is needed before routine recommendation in all patients.